scholarly journals Colorectal anastomotic perforation secondary to acute ruptured appendicitis presenting as septic arthritis

2019 ◽  
Vol 5 (2) ◽  
pp. 1
Author(s):  
Hryhoriy Bohdanovych Zhoba ◽  
Brian P. Fleischer ◽  
Wesley B. Vanderlan

Anastomotic leaks following abdominoperineal resection with rectal anastomosis become clinically significant in 2.9%-22% of cases. Local recurrence of cancer and local inflammation are the most common causes of these leaks . Colonic perforation presenting with suppurative involvement of the lower extremities has been previously reported. We describe herein the case of a colorectal anastomotic leak secondary to pathology-proved acute appendicitis presenting with suppurative necessitation causing right hip septic arthritis five years following lower anterior resection (LAR) for stage unspecified colorectal cancer. No similar case has been demonstrated in the surveyed literature.

2018 ◽  
Vol 88 (9) ◽  
pp. E649-E653 ◽  
Author(s):  
Suat Chin Ng ◽  
Douglas Stupart ◽  
David Bartolo ◽  
David Watters

PEDIATRICS ◽  
1983 ◽  
Vol 71 (1) ◽  
pp. 139-139
Author(s):  
J. M. WRIGHT

To the Editor.— The case report of carbamazepine intoxication secondary to isoniazid administration recently described in this journal1 is a clinically significant interaction. I have previously presented2 a similar case in which a patient receiving carbamazepine, valproate, and nitrazepam developed severe carbamazepine intoxication when isoniazid was added to the drug regimen. The patient was determined to have inherited the slow acetylator phenotype. On careful rechallenge, 300 mg of isoniazid increased carbamazepine steady-state serum concentrations by 85% and decreased carbamazepine clearance by 45%.


2019 ◽  
Vol 56 ◽  
pp. 15-22 ◽  
Author(s):  
Antonia K. Roseweir ◽  
Arfon G.M.T. Powell ◽  
Sheryl L. Horstman ◽  
Jitwadee Inthagard ◽  
James H. Park ◽  
...  

2017 ◽  
Vol 35 (19) ◽  
pp. 2173-2183 ◽  
Author(s):  
Marieke van de Wal ◽  
Belinda Thewes ◽  
Marieke Gielissen ◽  
Anne Speckens ◽  
Judith Prins

Purpose Fear of cancer recurrence (FCR) is a common problem experienced by cancer survivors. Approximately one third of survivors report high FCR. This study aimed to evaluate whether blended cognitive behavior therapy (bCBT) can reduce the severity of FCR in cancer survivors curatively treated for breast, prostate, or colorectal cancer. Patients and Methods This randomized controlled trial included 88 cancer survivors with high FCR (Cancer Worry Scale score ≥ 14) from 6 months to 5 years after cancer treatment. Participants were randomly allocated (ratio 1:1, stratified by cancer type) to receive bCBT, including five face-to face and three online sessions (n = 45) or care as usual (CAU; n = 43). Participants completed questionnaires at baseline (T0) and 3 months later (T1). The intervention group completed bCBT between T0 and T1. The primary outcome was FCR severity assessed with the Cancer Worry Scale. Secondary outcomes included other distress-related measures. Statistical (one-way between-group analyses of covariance) and clinical effects (clinically significant improvement) were analyzed by intention to treat. Results Participants who received bCBT reported significantly less FCR than those who received CAU (mean difference, –3.48; 95% CI, –4.69 to –2.28; P < .001) with a moderate-to-large effect size ( d = 0.76). Clinically significant improvement in FCR was significantly higher in the bCBT group than in the CAU group (13 [29%] of 45 compared with 0 [0%] of 43; P < .001); self-rated improvement was also higher in the bCBT group (30 [71%] of 42 compared with 12 [32%] of 38 in the CAU group; P < .001). Conclusion bCBT has a statistically and clinically significant effect on the severity of FCR in cancer survivors and is a promising new treatment approach.


Cancers ◽  
2020 ◽  
Vol 12 (11) ◽  
pp. 3481
Author(s):  
Rebecca A. Shuford ◽  
Ashley L. Cairns ◽  
Omeed Moaven

The genetic and molecular underpinnings of metastatic colorectal cancer have been studied for decades, and the applicability of these findings in clinical decision making continues to evolve. Advancements in translating molecular studies have provided a basis for tailoring chemotherapeutic regimens in metastatic colorectal cancer (mCRC) treatment, which have informed multiple practice guidelines. Various genetic and molecular pathways have been identified as clinically significant in the pathogenesis of metastatic colorectal cancer. These include rat sarcoma (RAS), epithelial growth factor receptor (EGFR), vascular endothelial growth factor VEGF, microsatellite instability, mismatch repair, and v-raf murine sarcoma viral oncogene homolog b1 (BRAF) with established clinical implications. RAS mutations and deficiencies in the mismatch repair pathway guide decisions regarding the administration of anti-EGFR-based therapies and immunotherapy, respectively. Furthermore, there are several emerging pathways and therapeutic modalities that have not entered mainstream use in mCRC treatment and are ripe for further investigation. The well-established data in the arena of targeted therapies provide evidence-based support for the use or avoidance of various therapeutic regimens in mCRC treatment, while the emerging pathways and platforms offer a glimpse into the future of transforming a precision approach into a personalized treatment.


2007 ◽  
Vol 205 (5) ◽  
pp. 648-653 ◽  
Author(s):  
Matthew G. Tytherleigh ◽  
Les Bokey ◽  
Pierre H. Chapuis ◽  
Owen F. Dent

Surgery Today ◽  
2012 ◽  
Vol 42 (11) ◽  
pp. 1082-1087 ◽  
Author(s):  
Hiroshi Sawayama ◽  
Shinjiro Tomiyasu ◽  
Kiichiro Kanemitsu ◽  
Takatsugu Matsumoto ◽  
Hideyuki Tanaka ◽  
...  

Blood ◽  
2011 ◽  
Vol 118 (21) ◽  
pp. 715-715
Author(s):  
Nicole H. Smith ◽  
Kate Henry ◽  
James C. Zimring ◽  
Jeanne E. Hendrickson

Abstract Abstract 715 Introduction: Pregnancy and transfusion induced RBC alloimmunization can be clinically significant, leading to difficulties with future transfusions and also leading to hemolytic disease of the fetus and newborn (HDFN). Maternal anti-Kell alloimmunization is one of the most common causes of non ABO-mediated HDFN. To date, there are few treatments to prevent HDFN due to RBC antibodies outside of the Rh(D) family, and there are few existing animal models of pregnancy induced RBC alloimmunization. Herein, we describe a novel murine model in which Kell RBC alloimmunization occurs following pregnancy or transfusion. Materials and Methods: Mice with RBC specific expression of the K2 allele of the human Kell glycoprotein (subsequently referred to as “K2” mice) were generated utilizing constructs containing the human K2 sequence expressed by beta-globin regulatory elements. For the transfusion induced alloimmunization experiments, C57BL/6 female recipients were transfused 3 times with K2 RBCs in the presence of poly (I:C), with anti-Kell glycoprotein antibodies measured after each transfusion by flow cytometric crossmatch using K2 targets and subtype specific antibodies. For the pregnancy induced alloimmunization experiments, control naïve C57BL/6 females were mated with K2 males three times; females immunized following transfusion were mated with K2 males as well. After the final pregnancy, anti-Kell glycoprotein antibodies were also measured by flow cytometric. Number and percentage of K2 positive pups were noted in a subset of pregnancies, and deceased pups were genotyped by PCR. Results: Anti-Kell glycoprotein antibodies were detectable in C57BL/6 recipients following either K2 RBC transfusion or following repeat pregnancies with K2 positive fetuses. In 5 experiments, 30/30 transfused mice had anti-Kell antibody titers that increased with subsequent transfusion, with IgM, IgG1, IgG2b, IgG2c, and IgG3 anti-Kell being detectable. After 2–3 pregnancies with K2 mates, 11/12 C57BL/6 females developed anti-Kell glycoprotein antibodies, with IgM and all IgG anti-Kell subtypes being present. Regardless of the mechanism of immunization (e.g. transfusion or prior pregnancy), live births and pups surviving beyond day of life #2 were lower in Kell immunized mothers compared with control non-immunized mothers (approximately 2–4 pups compared to 6–10 pups). At least one K2 stillborn pup had severe edema resembling hydrops. Discussion: This is the first animal model of Kell RBC alloimmunization, in which anti-Kell can be generated either through prior pregnancy or transfusion and appears to be detrimental to pups. This model mimics that of pregnancy or transfusion induced anti-Rh(D), in that the described antigen (K2) is largely foreign to the C57BL/6 recipients (who lack human K1 or K2 altogether). Ongoing studies are investigating whether a particular method of immunization (e.g. pregnancy vs transfusion) is more detrimental to fetuses and pups. As expected, the anti-Kell antibody appears more detrimental to K2 positive than negative fetuses, with immunized mothers having smaller litters of predominantly K2 negative fetuses; however, K2 negative pups may also have higher rates of demise following birth to immunized compared to non-immunized mothers. In sum, this model will allow for further investigation of pregnancy and transfusion induced anti-Kell RBC alloimmunization, and may also serve to increase the understanding of the pathogenesis and prevention of HDFN. Disclosures: Zimring: Immucor: Funds from an Immucor sponsored project (unrelated to the current project) were utilized in part to generate the KEL transgenic animals.


Sign in / Sign up

Export Citation Format

Share Document